Is there an Indian generic version of Alpelisib available and is it cheaper?

Alpelisib (Alpelisib) is a PI3Kα inhibitor, mainly used to treat PIK3CA mutated hormone receptor-positive HER2 negative advanced breast cancer patients. Globally, as an important member of targeted therapy, it has been approved for marketing by the US FDA. However, as of now, Apelvis has not been officially launched in mainland China, which means that domestic patients cannot directly purchase the drug through regular hospitals or pharmacies, and can only obtain it through overseas channels, which brings certain inconvenience and financial burden to patient treatment.

Although India is an important global production base for generic drugs, there is currently no generic version of Apelvis in India. What is sold in the Indian market is still the original version of the drug, which is produced under license from Novartis. The price of the original Indian drug has dropped compared with the European and American markets, but the price is still around 3,000 yuan, which is still a considerable expense for breast cancer patients undergoing long-term treatment. Since no generic drugs have entered the market, prices are unlikely to fall further in the short term.

In the absence of generic drugs in India, some patients are turning to other countries to find more affordable alternatives. It is worth noting that a pharmaceutical company in Laos has launched a generic version of Apelvis. The price of this generic drug is about more than 1,000 yuan per box, which is nearly two-thirds lower than the original version in India. Although it is a generic version, this type of drug is relatively consistent with the original drug in terms of generic standards, drug ingredients and clinical use feedback, making it the practical choice for many patients with limited economic conditions.

For patients who need Apelvis treatment, if the budget is sufficient, they can choose the original Indian drug, whose efficacy and quality are guaranteed; while patients with greater financial pressure can also consider obtaining the Laotian generic version through formal channels. No matter which drug you choose, it is recommended that you use it under the guidance of a professional doctor and pay attention to the formality of the source of the drug to avoid counterfeit or inferior drugs that may affect the treatment effect or cause safety issues. With the acceleration of the domestic approval process, Apelvis is expected to be launched in China and included in medical insurance in the future, and patients' medication burden is expected to be further reduced.

Reference materials:https://www.drugs.com/